McKesson stock trades near record levels as oncology and pharmacy businesses support earnings momentum

McKesson stock is trading close to record territory as the US healthcare distributor benefits from steady revenue growth, margin expansion, and shareholder returns driven by oncology and pharmacy services.

McKesson Corporation (ISIN US58155Q1031) is one of the largest healthcare distributors in the United States, and McKesson stock has been trading near record levels on the New York Stock Exchange in recent months as the company benefits from strong demand for pharmaceuticals and oncology services. As of 30 June 2026, the company carried a market capitalization in the tens of billions of US dollars according to public market data, underlining its role as a core component of the US healthcare and distribution sector.

Revenue above USD 300 billion

According to McKesson's latest annual report for fiscal 2025, the company generated revenue of more than $300 billion, continuing a trend of high single-digit growth compared with prior years. In fiscal 2024, McKesson's revenue had already exceeded $290 billion, so the most recent figures indicate an increase of more than $10 billion year on year. This revenue expansion reflects the company's broad role in distributing branded, generic, and specialty pharmaceuticals to pharmacies, hospitals, and oncology practices across North America.

Operating profit also improved. In fiscal 2025, McKesson reported operating income of several billion dollars, an increase of more than ten percent compared with the previous year. The margin progression is important: the company has been shifting its business mix toward higher-margin clinical and technology services, particularly in oncology and pharmacy solutions. The improvement in operating income relative to revenue indicates that this strategy has begun to show through in the numbers, even though distribution remains a low-margin business in absolute terms.

EPS growth versus prior year

On the earnings side, McKesson reported adjusted earnings per diluted share (EPS) in fiscal 2025 that were meaningfully higher than the prior year. The company has a track record of growing adjusted EPS by double-digit percentages, and in fiscal 2025 the increase versus fiscal 2024 amounted to several dollars per share. For investors, EPS growth matters because it signals that management is finding ways to convert revenue expansion and margin improvement into shareholder returns despite the capital intensity and competitive pressure in healthcare distribution.

McKesson's quarterly performance in fiscal 2025 showed similar trends. In one of the recent quarters, revenue grew mid-single digits year on year, while adjusted EPS rose at a faster pace thanks to cost discipline and the contribution from oncological services. This quarterly pattern illustrates how the company is leveraging scale and technology to grow earnings faster than top-line revenue. The quantified comparison against the prior year quarter is a key data point for analysts evaluating the sustainability of the earnings trajectory.

Share repurchases and capital returns

McKesson has also been active in returning capital to shareholders. In fiscal 2025, the company spent several billion dollars on share repurchases, reducing the diluted share count and supporting EPS growth. The repurchase activity in fiscal 2025 was higher than in fiscal 2024, when the company had already returned substantial capital via buybacks. This incremental increase in capital returns signals management's confidence in the long-term cash generation of the business and its willingness to use excess cash to enhance per-share metrics.

Alongside buybacks, McKesson has maintained a modest but growing dividend. The annual dividend per share in fiscal 2025 was slightly higher than in fiscal 2024, continuing a pattern of gradual increases. While the dividend yield remains relatively low compared with some other sectors, the combination of buybacks and dividend growth is an important element of the total return profile for McKesson stock.

Oncology and pharmacy services drive mix

One of McKesson's key strategic areas is oncology. The company operates a large oncology network, providing practice management, distribution, and clinical support services to cancer treatment centers. In recent years, oncology-related revenue has grown faster than the company's overall revenue, contributing to a gradual shift in the business mix. The oncology segment has also delivered higher operating margins than traditional wholesale distribution, making it a focus area for future growth.

Pharmacy services are another contributor. McKesson provides a range of support services to independent and chain pharmacies, including inventory management, technology solutions, and reimbursement support. Revenue from pharmacy services has increased compared with prior years, although it remains a smaller portion of the total than core distribution. However, this segment helps diversify the company's revenue base and offers opportunities for cross-selling technology and data solutions.

Strong position in US healthcare distribution

McKesson is one of three major pharmaceutical distributors in the United States, alongside other large players in the sector. Its scale allows it to negotiate favorable terms with manufacturers and to provide reliable distribution services to pharmacies, hospitals, and clinics. The company's infrastructure includes dozens of distribution centers and advanced logistics systems designed to ensure timely delivery of medications across the country.

In the context of the broader healthcare system, McKesson plays an important role in ensuring access to medications, including vaccines and specialty drugs. The company has participated in large-scale distribution programs for vaccines in recent years, which have contributed to revenue and showcased its ability to manage complex logistics. This operational capability is a competitive advantage that underpins McKesson stock's status as a key healthcare holding for many institutional investors.

Shares near historical highs

McKesson stock has appreciated significantly over the past several years, reflecting the company's earnings growth and capital returns. As of late June 2026, the share price was trading close to historical highs on the NYSE. This level places the stock well above its levels from three years earlier, when the market was still assessing the long-term impact of pandemic-related disruptions on healthcare distribution.

The share price performance has also been supported by valuation re-rating. The market has gradually assigned higher multiples to McKesson's earnings as investors gained confidence in the company's strategic shift toward higher-margin services. While the stock is no longer trading at the discounted valuations seen several years ago, its current levels reflect a balance between earnings growth prospects and the defensive characteristics of healthcare distribution.

Comparison with sector peers

Compared with other large US healthcare distributors, McKesson has delivered a strong combination of revenue growth and EPS expansion. In fiscal 2025, its revenue growth rate was broadly in line with peers, but its EPS growth outpaced some competitors thanks to a more pronounced focus on specialty and oncology services. This performance has been reflected in relative share price trends, with McKesson stock outperforming certain peers over a multi-year period.

Analysts following the sector often highlight differences in business mix as a key driver of earnings quality. McKesson's emphasis on oncology and pharmacy solutions, along with technology offerings, provides multiple levers for margin improvement beyond pure volume growth in distribution. The quantified comparisons in revenue and EPS growth versus sector averages are therefore central to understanding how McKesson positions itself within the competitive landscape.

Regulatory and reimbursement environment

Like all healthcare distributors, McKesson operates under a complex regulatory and reimbursement framework. Changes in drug pricing rules, reimbursement rates, and contract structures can affect revenue and margins. Over the past few years, the company has managed to navigate these changes while still delivering revenue growth and EPS expansion. However, regulatory developments remain a key risk factor that investors monitor closely.

McKesson has also engaged with policymakers and industry groups to shape discussions around drug distribution and access. Its role as a major distributor gives it insight into how changes in reimbursement policies may affect pharmacies and providers. For investors, understanding the regulatory backdrop is important for assessing the sustainability of the financial metrics reported in the company's annual and quarterly results.

Digital and data initiatives

Beyond physical distribution, McKesson has invested in digital and data capabilities to support pharmacies and oncology practices. Technology solutions help clients manage inventory, analyze prescription trends, and improve reimbursement processes. Revenue from technology and data services has grown over recent years, contributing to the company's overall revenue and offering another avenue for margin enhancement.

These initiatives also support long-term relationships with clients. By providing technology and data solutions, McKesson can embed itself more deeply into clients' workflows, making it more difficult for competitors to displace its services. The financial impact of these digital initiatives is visible in the company's segment reporting, where revenues from services and technology have increased compared with prior years.

Focus on operational efficiency

Operational efficiency is a key driver of McKesson's financial performance. The company has pursued cost optimization programs, including consolidation of distribution centers, automation, and improvements in procurement. These measures have contributed to operating income growth that exceeds revenue growth, as noted in the comparison between fiscal 2025 and fiscal 2024.

In addition, McKesson has worked to improve working capital management. Changes in inventory and receivables have been managed to support free cash flow generation. The company's ability to convert earnings into cash underpins its capacity to fund share repurchases and dividends. Quantified metrics for cash flow and working capital are therefore important elements of investor analysis, even if they receive less headline attention than revenue and EPS.

Strategic portfolio adjustments

McKesson has periodically adjusted its portfolio, divesting non-core assets and acquiring businesses that support its focus on oncology and pharmacy services. These strategic moves can affect revenue and earnings in the short term, but are aimed at strengthening the company's competitive position. For example, divestitures of lower-margin or non-strategic units may reduce revenue but can improve overall margin, contributing to EPS growth.

Acquisitions in specialty distribution or technology can add incremental revenue and capabilities. When evaluating McKesson stock, investors consider not only reported metrics but also the underlying portfolio changes that shape future earnings potential. The quantified impact of acquisitions and divestitures on revenue and operating income is therefore another piece of the puzzle.

Balance sheet and debt profile

McKesson's balance sheet shows a mix of short-term and long-term debt, alongside cash and equivalents. The company's leverage is moderate relative to its cash flow, enabling it to pursue capital returns without compromising financial flexibility. Debt levels have remained manageable in recent years, and interest expense has been stable relative to operating income.

The company's credit profile is an important consideration for institutional investors. Ratings agencies monitor metrics such as debt-to-EBITDA and interest coverage. McKesson's ability to maintain a solid credit profile while returning capital via buybacks and dividends is one of the reasons its stock is regarded as a relatively defensive holding in the healthcare sector.

Dividends and shareholder yield

While McKesson's dividend yield is modest, the combination of dividends and share repurchases creates a significant shareholder yield. The company has increased its dividend per share gradually, and buyback activity has remained strong. The sum of dividends and buybacks as a percentage of market capitalization provides a useful metric for assessing how much cash is returned to shareholders each year.

For long-term holders, this capital return policy complements the company's earnings growth. Over a multi-year horizon, the combination of EPS growth and shareholder yield can support total returns that compare favorably with broader market indices. This perspective is important for understanding why McKesson stock features in many diversified portfolios.

Guidance and outlook

McKesson typically provides annual guidance for revenue and adjusted EPS, offering a framework for market expectations. In its latest guidance, the company projected continued revenue growth and EPS expansion, consistent with recent trends. The guidance ranges reflect assumptions about drug volume, pricing, and the performance of oncology and pharmacy services.

For investors, the quantified guidance is a reference point when evaluating quarterly and annual results. Comparing actual results with guidance helps assess management's forecasting accuracy and the resilience of the business model. When results exceed or fall short of guidance, share price reactions can be significant, underscoring the importance of these metrics.

Risk factors and uncertainty

Despite its strong position, McKesson faces several risk factors that could affect future financial performance. These include changes in healthcare regulation, competitive pressure in distribution and services, potential litigation, and macroeconomic conditions that influence healthcare spending. Investors consider how these risks might impact revenue, margins, and cash flow when assessing the long-term outlook for McKesson stock.

Risk disclosures in the company's annual report provide detailed descriptions of these factors. While quantitative metrics such as revenue and EPS give a snapshot of current performance, understanding the qualitative risk environment is essential for interpreting the sustainability of these numbers.

Revenue and margin decide

Ultimately, the key drivers for McKesson stock are revenue growth and margin progression. The company's ability to expand revenue in a mature market, while improving margins through oncology, pharmacy services, and technology, is central to its investment case. The quantified comparisons in revenue, operating income, and EPS versus prior years are therefore the numbers that most investors watch closely.

If McKesson can continue to deliver high single-digit revenue growth and double-digit EPS expansion, supported by capital returns and disciplined balance sheet management, its stock may remain an important holding for investors seeking exposure to the healthcare distribution and services space.

Oncology network and services

McKesson's oncology network brings together independent oncology practices across the United States, providing them with distribution, clinical support, and practice management services. Revenue from oncology services has grown faster than the company average, contributing disproportionately to operating income. This growth reflects rising demand for cancer treatments, including complex biologic and specialty drugs, and the need for practices to manage reimbursement and clinical pathways efficiently.

The oncology business also includes technology tools that help physicians track treatment protocols and outcomes. By integrating these tools into practice workflows, McKesson enhances the value of its services and deepens client relationships. The financial contribution of oncology is therefore not only in direct distribution revenue but also in service and technology fees.

McKesson stock and NYSE listing

McKesson stock is listed on the New York Stock Exchange, where it trades under its established ticker symbol. As of late June 2026, the share price on the NYSE was in the high hundreds of dollars per share, measured in USD. This price places McKesson among the higher-priced individual stocks in the healthcare sector, reflecting both its large market capitalization and its long-term share price appreciation.

The NYSE listing ensures high liquidity for McKesson stock, with daily trading volumes sufficient to accommodate both institutional and retail investors. The trading venue also provides visibility for the company within major US equity indices, even though McKesson's specific index memberships depend on periodic rebalancing decisions by index providers.

McKesson key data

• Company: McKesson Corporation
• ISIN: US58155Q1031
• Ticker: NYSE: MCK
• Trading venue: NYSE
• Price (as of 30 June 2026, 16:00 ET): high hundreds USD
• Market capitalization: tens of billions USD (as of 30 June 2026)
• Sector / Industry: Health Care / Health Care Providers and Services
• Index membership: major US equity indices